Two Kidney Tests Tell Different Stories—And That Matters for Your Health

When two standard kidney function tests give conflicting results, it's not just a medical curiosity—it's a warning sign that could save your life. A major new study involving over 800,000 people found that patients whose kidney tests disagreed by 30% or more faced significantly higher risks of death, heart disease, and kidney failure.

What Are These Two Kidney Tests?

Doctors typically measure kidney function using estimated glomerular filtration rate (eGFR), which shows how well your kidneys filter waste from your blood. This can be calculated using two different blood markers: creatinine (a byproduct of muscle metabolism) or cystatin C (a small protein). While both measure kidney function, various factors can influence each test differently, sometimes producing conflicting results for the same person.

How Often Do These Tests Disagree?

The research team, led by Drs. Morgan Grams and Josef Coresh at New York University Grossman School of Medicine, discovered that test disagreement is surprisingly common. Among outpatients, about 11% had cystatin C-based results that were at least 30% lower than their creatinine-based results. The numbers were even higher for hospitalized patients, with 35% showing this significant discrepancy.

The researchers tracked participants for an average of 11 years and found alarming patterns. Those with large differences between their test results faced increased risks across multiple health outcomes:

• Death Risk: Higher likelihood of dying from any cause during the study period
• Cardiovascular Disease: Increased risk of developing heart disease and dying from it
• Heart Failure: Elevated risk of this serious heart condition
• Kidney Failure: Greater chance of complete kidney failure requiring dialysis or transplant

Interestingly, the study also found a protective effect. Outpatients whose cystatin C-based eGFR was at least 30% higher than their creatinine-based eGFR actually had lower risks for most health problems compared to those with smaller differences between tests.

Why Should You Care About This Discovery?

"Our findings highlight the importance of measuring both creatinine and cystatin C to gain a true understanding of how well the kidneys are working, particularly among older and sicker adults," explains Dr. Grams. "Since neither test is perfect, evaluating both biomarkers may identify far more people with poor kidney function, and earlier in the disease process, allowing for preventative intervention."

This research suggests that using both tests together could revolutionize how doctors identify patients at risk. Currently, many healthcare providers rely on just one test, potentially missing critical warning signs. The larger the difference between the two test results, the greater the health risks, making this a powerful tool for early intervention.

With more than 35 million Americans living with chronic kidney disease (CKD), this finding could help identify high-risk patients who need more intensive monitoring and treatment. The study's massive scale—analyzing data from the NIH-funded Chronic Kidney Disease Prognosis Consortium that has been collecting global kidney health data since 2009—gives these results significant weight in the medical community.